Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes
Authors:
- 25 March 2015
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 17 (6) , 541-545
Abstract
Aims: To assess the glucose‐stimulated insulin secretion effect of imeglimin in patients with type 2 diabetes. Methods: We conducted a double‐blind, randomized, placebo‐controlled study in 33 patients with type 2 diabetes [glycated haemoglobin 6.8 ± 0.1% (51 mmol/mol)], who were drug‐naïve or withdrawn from their previous metformin monotherapy for 2 weeks and received imeglimin 1500 mg twice daily or placebo for 1 week. Glucose‐stimulated insulin secretion was assessed using a hyperglycaemic clamp. The primary endpoint was insulin secretion as defined by total insulin response [incremental area under the curve ( iAUC ) 0–45 min ] and insulin secretion rate ( ISR ) calculated from C‐peptide deconvolution. β‐cell glucose sensitivity at steady state (second phase: 25–45 min), hepatic insulin extraction and insulin clearance were also calculated. Results: Imeglimin treatment for 7 days raised the insulin secretory response to glucose by +112% ( iAUC 0‐45 , p = 0.035), first‐phase ISR by +110% (p = 0.034) and second‐phase ISR by +29% (p = 0.031). Imeglimin improved β‐cell glucose sensitivity by +36% (p = 0.034) and tended to decrease hepatic insulin extraction (−13%; p = 0.056). Imeglimin did not affect glucagon secretion. Conclusions: In patients with type 2 diabetes, imeglimin improves β‐cell function, which may contribute to the glucose‐lowering effect observed with imeglimin in clinical trials.Keywords
Funding Information
- Poxel
This publication has 17 references indexed in Scilit:
- The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin MonotherapyDiabetes Care, 2013
- Mechanism of Action of DPP-4 Inhibitors—New InsightsThe Journal of Clinical Endocrinology & Metabolism, 2012
- Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patientsDiabetes, Obesity and Metabolism, 2012
- Twelve weeks treatment with the DPP‐4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non‐glucose induced insulin secretion in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2010
- Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 DiabetesDiabetes Care, 2009
- One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 DiabetesDiabetes, 2004
- Methods for clinical assessment of insulin sensitivity and β-cell functionBest Practice & Research Clinical Endocrinology & Metabolism, 2003
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurementsJournal of Clinical Periodontology, 1988
- Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.Journal of Clinical Investigation, 1981